Lipodystrophy syndrome: Diagnostic, clinic and therapeutic aspects

AIDS Reviews

Volumn 3, Issue 2, 2001, Pages 98-105

  Blanco, F ^a   Carr, A ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiretroviral toxicity; Cardiovascular risk; Dyslipidaemia; HAART; Lactic acidaemia; Lipodystrophy

Indexed keywords

ABACAVIR; ALPHA TOCOPHEROL; ANABOLIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ASCORBIC ACID; DIDANOSINE; EFAVIRENZ; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOCORTICOID; GLUCOSE; HYDROXYUREA; INSULIN; LAMIVUDINE; LIPID; METFORMIN; NEVIRAPINE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PROTEINASE INHIBITOR; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIAMINE; UBIDECARENONE; UNINDEXED DRUG; ZIDOVUDINE;

ATHEROSCLEROSIS; BODY BUILD; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; EXERCISE; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE SYSTEM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LACTIC ACIDEMIA; LACTIC ACIDOSIS; LIPID METABOLISM; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; MEDICAL DECISION MAKING; METABOLIC DISORDER; MORBIDITY; MORPHOLOGY; MORTALITY; PRESCRIPTION; PREVALENCE; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL ASPECT; TREATMENT OUTCOME;

EID: 0035204053     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome
2. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
3. "Buffalo hump" in men with HIV-1 infection
4. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients
5. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
6. Visceral abdominal-fat accumulation associated with use of indinavir
7. Adverse effects of antiretroviral therapy
8. HIV protease inhibitor-induced lipodystrophy syndrome
9. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
10. Lipodystrophy in patients naive to HIV protease inhibitors
11. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
12. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
13. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
14. Longitudinal analysis of bone mineral density (BMD) in HIV-infected patients treated with HAART: Changes in BMD correlate with change in subcutaneous fat; with an additional independent effect of indinavir therapy to increase BMD
15. Osteopenia in HIV-infected men: Association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy
16. Development of cervical fat pads following therapy with HIV-1 protease inhibitors
17. Buffalo humps associated with protease inhibitors
18. Benign symmetric lipomatosis associated with protease inhibitors
19. Another case of breast hypertrophy in a patient treated with indinavir
20. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection
21. Gynecomastia associated with indinavir therapy
22. Hypertriglyceridemia in the acquired immunodeficiency syndrome
23. Fat distribution and metabolic changes in patients with HIV infection
24. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
25. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
26. Severe diabetes associated with protease inhibitor therapy
27. Diabetes mellitus associated with protease inhibitor use
28. Abacavir and diabetes
29. Lactate levels in HIV-positive patients under antiretroviral treatment
30. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
31. Lipodystrophy syndrome definition: A search for consistency
32. Ability of anthropometry to detect changes in body fat distribution
33. Conventional anthropometric measures are poor reflectors of clinical lipodystrophy
34. Sonographic assessment of regional fat in HIV-infected people
35. The Australian lipodystrophy prevalence survey
36. Metabolic side effects of antiretroviral therapy in the Swiss cohort study
37. Description of lipodystrophy in the HIV Outpatient Study (HOPS)
38. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS)
39. Incidence of clinical lipodystrophy in HIV-1 infected patients treated during primary infection
40. Lipodystrophy and metabolic disorders in HIV-infected patients treated by protease inhibitors: Is there an association?
41. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: A cross-sectional analysis
42. The SENC (Spanish Efavirenz vs Nevirapine Comparison) trial: Preliminary results of a prospective, randomized, controlled, open-label study in HIV+ naive individuals
43. Cardiovascular risk in HIV-positive patients with HAART-related dyslipidemia. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto 2000
44. Characterization of metabolic abnormalities and coronary artery disease risk factors in HIV-infected men and women with lipodystrophy
45. Do protease inhibitors increase the risk for coronary heart disease among HIV-positive patients (follow-up through June 2000)
46. Impact of treatment with protease inhibitors on myocardial infarction occurrence in HIV-infected men
47. Use of HIV protease inhibitors is associated with endothelial dysfunction. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto 2000
48. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
49. Premature arteriosclerosis in HIV-infected individuals - focus on protease inhibitor therapy
50. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection
51. Ritonavir, triglycerides and pancreatitis
52. Hyperlactatemia in HIV-infected patients: The role of NRTI treatment
53. State-of-the-art summary and discussion issues in metabolic complications: Controversy or consensus
54. Lactic acidosis associated with stavudine administration: A report of five cases
55. Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy
56. Hepatomegaly with severe steatosis in HIV-seropositive patients
57. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
58. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
59. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz
60. Impact of switching from HIV-1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
61. Use of Trizivir to simplify therapy in HAART-experienced patients with long-term suppression of HIV-RNA: TRIZAL study (AZL30003)-24-week results
62. Switching from PI to ABC improves insulin sensitivity and fasting lipids-12 months follow-up
63. Switching to efavirenz from protease inhibitor-based therapy does not improve insulin resistance after one year in HIV patients with lipodystrophy syndrome
64. Risks and benefits of replacing PI by NVP in HIV+ subjects under long-term successful treatment
65. The Maintavir Study, substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients with undetectable plasma HIV-1 RNA: 18 months follow-Up
66. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: A 52-week, multicenter, prospective study.
67. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: 52-week, multicenter, prospective study
68. The role of abacavir in antiretroviral therapy-experienced patients: Results from a randomized, double-blind, trial. CNA3002 European Study Team
69. Decreased HIV-associated T-cell apoptosis by HIV protease inhibitors
70. Structured antiretroviral therapy interuption as a form of immune-based therapy in HIV-1 infection
71. Structured antiretroviral treatment interruption in heavily-experienced HIV-infected patients
72. The role of hydroxiurea in the treatment of HIV infection
73. Monthly cyclic therapy in heavily pre-treated HIV-infected patients
74. Metabolic complications of HAART: Need for perspective
75. Nevirapine containing potent antiretroviral therapy results in an anti-athegenic plasma lipid profile: Results from the Atlantic Trial
76. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the ACTG Cardiovascular Disease Focus Group
77. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
78. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
79. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
80. Lipid lowering therapy in patients with HIV infection
81. A randomized open label comparative trial of dietary advice with and without pravastatin for the management of protease inhibitor-associated hypercholesterolemia
82. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidemias: A pilot study
83. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy
84. Metformin in the treatment of HIV lipodystrophy syndrome. A randomized controlled trial
85. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
86. Management of hyperlactatemia: No need for routine lactate measurements
87. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options
88. Riboflavin and severe lactic acidosis
89. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV
90. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone
91. Long-term follow-up of patients with HARS receiving rhGH: Another dilemma of early versus delayed intervention?
92. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
93. The effects of polylactic acid as therapy for lipoatrophy of the face